Abstract:Ameloblastoma (AM) is a prominent benign odontogenic tumor characterized by aggressiveness, likely originating from tooth-generating tissue or the dental follicle (DF). However, proteomic distinctions between AM and DF remain unclear. In the present study, the aim was to identify the distinction between AM and DF in terms of their proteome and to determine the associated hub genes. Shotgun proteomics was used to compare the proteomes of seven fresh-frozen AM tissues and five DF tissues. Differentially expressed proteins (DEPs) were quantified and subsequently analyzed through Gene Ontology-based functional analysis, protein-protein interaction (PPI) analysis and hub gene identification. Among 7,550 DEPs, 520 and 216 were exclusive to AM and DF, respectively. Significant biological pathways included histone H2A monoubiquitination and actin filament-based movement in AM, as well as pro-B cell differentiation in DF. According to PPI analysis, the top-ranked upregulated hub genes were ubiquitin C (UBC), breast cancer gene 1 (BRCA1), lymphocyte cell-specific protein-tyrosine kinase (LCK), Janus kinase 1 and ATR serine/threonine kinase, whereas the top-ranked downregulated hub genes were UBC, protein kinase, DNA-activated, catalytic subunit (PRKDC), V-Myc avian myelocytomatosis viral oncogene homolog (MYC), tumor protein P53 and P21 (RAC1) activated kinase 1. When combining upregulated and downregulated genes, UBC exhibited the highest degree and betweenness values, followed by MYC, BRCA1, PRKDC, embryonic lethal, abnormal vision, Drosophila, homolog-like 1, myosin heavy chain 9, amyloid beta precursor protein, telomeric repeat binding factor 2, LCK and filamin A. In summary, these findings contributed to the knowledge on AM protein profiles, potentially aiding future research regarding AM etiopathogenesis and leading to AM prevention and treatment.

Advancements in MAPK signaling pathways and MAPK-targeted therapies for ameloblastoma: A review

Anti-MAPK Targeted Therapy for Ameloblastoma: Case Report with a Systematic Review

BRAF V600E mutation mediates invasive and growth features in ameloblastoma

Molecular pathogenesis of ameloblastoma

Research Advances in the V-Raf Murine Sarcoma Viral Oncogene Homolog Gene Mutation in Ameloblastoma

Association of MDM2 Overexpression in Ameloblastomas with MDM2 Amplification and BRAFV600E Expression

Clinicopathological characteristics and diagnostic accuracy of BRAF mutations in ameloblastoma: A Bayesian network analysis

Exploiting BRAF mutations in the therapeutic approach towards oral and maxillofacial tumors

Tumor microenvironment of ameloblastoma with a focus on osteoclastogenesis, cell migration, and malignant transformation

METTL1 facilitates ameloblastoma invasive growth via MAPK signaling pathway

Targeted therapies in ameloblastomas and amelobastic carcinoma—A systematic review

The MAPK pathway across different malignancies: A new perspective

Mitogen-activated Protein Kinase Signaling Pathway in Oral Cancer (Review)

BRAF Inhibitor: a Novel Therapy for Ameloblastoma in Mandible

Enrichment of SOX2-Positive Cells in BRAF V600E Mutated and Recurrent Ameloblastoma

Molecular Markers of Tumor Invasiveness in Ameloblastoma: an Update.

Exploring protein profiles and hub genes in ameloblastoma

Extracellular signal-regulated kinases modulate DNA damage response - a contributing factor to using MEK inhibitors in cancer therapy.

Whole Exome Sequencing and System Biology Analysis Support the "Two-Hit" Mechanism in the Onset of Ameloblastoma

Targeting RAS/RAF/MEK/ERK Signaling in Metastatic Melanoma

Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers